Leerink Partnrs Forecasts Xeris Biopharma Q2 Earnings

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - Stock analysts at Leerink Partnrs issued their Q2 2025 earnings per share (EPS) estimates for Xeris Biopharma in a research report issued to clients and investors on Monday, May 12th. Leerink Partnrs analyst R. Ruiz expects that the company will post earnings per share of ($0.01) for the quarter. The consensus estimate for Xeris Biopharma's current full-year earnings is ($0.41) per share. Leerink Partnrs also issued estimates for Xeris Biopharma's Q3 2025 earnings at $0.03 EPS, Q4 2025 earnings at $0.04 EPS, FY2025 earnings at $0.00 EPS, FY2026 earnings at $0.20 EPS, FY2027 earnings at $0.40 EPS and FY2028 earnings at $0.65 EPS.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. The business had revenue of $57.80 million for the quarter, compared to analysts' expectations of $57.61 million.

Other equities research analysts have also issued reports about the stock. Jefferies Financial Group reaffirmed a "buy" rating and issued a $6.00 price target (up from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. Oppenheimer upped their target price on Xeris Biopharma from $6.00 to $7.00 and gave the stock an "outperform" rating in a research note on Friday, May 9th. HC Wainwright reaffirmed a "buy" rating and set a $8.00 target price (up from $6.60) on shares of Xeris Biopharma in a report on Friday, March 7th. Craig Hallum boosted their price target on Xeris Biopharma from $5.00 to $6.50 and gave the company a "buy" rating in a report on Friday, March 7th. Finally, Piper Sandler restated a "neutral" rating and issued a $4.00 price objective (up previously from $3.00) on shares of Xeris Biopharma in a research report on Friday, March 7th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Xeris Biopharma has a consensus rating of "Moderate Buy" and a consensus price target of $6.25.

Xeris Biopharma Stock Performance

Shares of Xeris Biopharma stock traded up $0.13 during trading on Thursday, hitting $5.00. 713,357 shares of the company's stock were exchanged, compared to its average volume of 2,611,692. The stock has a market capitalization of $781.14 million, a price-to-earnings ratio of -11.01 and a beta of 1.10. The business has a 50-day simple moving average of $4.73 and a 200-day simple moving average of $3.93. Xeris Biopharma has a 52-week low of $1.86 and a 52-week high of $6.07.

Insider Activity

In other Xeris Biopharma news, insider Beth Hecht sold 40,000 shares of the stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $5.43, for a total transaction of $217,200.00. Following the transaction, the insider now directly owns 1,353,510 shares of the company's stock, valued at $7,349,559.30. This trade represents a 2.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 6.47% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of XERS. Barclays PLC boosted its stake in shares of Xeris Biopharma by 87.8% in the third quarter. Barclays PLC now owns 324,472 shares of the company's stock worth $925,000 after acquiring an additional 151,685 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in Xeris Biopharma by 20.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 391,960 shares of the company's stock valued at $1,117,000 after purchasing an additional 67,557 shares in the last quarter. SG Americas Securities LLC lifted its holdings in Xeris Biopharma by 57.3% in the 4th quarter. SG Americas Securities LLC now owns 94,671 shares of the company's stock valued at $321,000 after purchasing an additional 34,469 shares in the last quarter. Janney Montgomery Scott LLC boosted its stake in Xeris Biopharma by 31.4% during the 4th quarter. Janney Montgomery Scott LLC now owns 23,000 shares of the company's stock worth $78,000 after purchasing an additional 5,500 shares during the last quarter. Finally, Goldstein Advisors LLC grew its holdings in shares of Xeris Biopharma by 24.2% during the fourth quarter. Goldstein Advisors LLC now owns 37,800 shares of the company's stock worth $128,000 after buying an additional 7,375 shares in the last quarter. 42.75% of the stock is owned by hedge funds and other institutional investors.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.